Prof Ranjit Manchanda Consultant Profile
Prof Ranjit Manchanda is Professor of Gynaecological Oncology at the Wolfson Institute of Preventive Medicine, Barts CRUK Cancer Centre, Queen Mary University of London, and Consultant Gynaecological Oncologist at Barts and the Royal London Hospital.
Ranjit completed his PhD in Gynaecological Oncology at University College London (UCL). He completed a NIHR Clinical Academic Lectureship at UCL and speciality training in gynaecological oncology at University College London Hospital (UCLH) and St Bartholomew’s Hospital (Barts Health).
He is a NHS Innovation Accelerator (NIA) Fellow. He leads the high-risk women’s Precision Prevention service at Barts Health and is chair of the London Cancer High risk Gynaecological Cancer MDT. He is a member of the NCRI Ovarian Cancer Surgical Sub group.
He has a keen interest in ultra-radical debulking surgery for ovarian cancer as well as minimal access surgery. He is a member of a number of advisory bodies and oversight committees.
He is co-Lead for the Cancer Prevention Theme at the Barts CRUK Cancer Centre. He was recently appointed as Speciality Research Lead for Gynaecological Cancer, NIHR North Thames Clinical Research Network (CRN). He is the Integrated Academic Training Programme Director, London Speciality School of Obstetrics & Gynaecology, Health Education England. He is the Lead for the RCOG Advanced Professional Module (APM) in Clinical Research for North Central and North East London.
He is a member of the International Gynaecological Cancer Society (IGCS) Education Steering Committee and Deputy-Director of the Barts Health RCOG sub-speciality training programme in gynaecological oncology. He has led a number of training initiatives in Gynaecological Oncology across Europe. He has served as President of the European Network of Young Gynaecological Oncologists (ENYGO) and member of the European Society of Gynaecological Oncology (ESGO) Council from 2011 – 2013.
Ranjit’s research interests are focused around Targeted Precision Prevention. This includes population-based germline testing, mainstreaming and precision medicine approaches for risk prediction, stratification, and targeted screening & cancer prevention.